title: Use of clozapine in tardive dystonia.
abstract: 1. This open clinical trial (N = 7) measured the course of severe tardive dystonia in chronic psychiatric patients after discontinuation of neuroleptics and subsequent use of clozapine. 2. The dystonia was regularly assessed using the Fahn-Marsden Rating Scale. The eventual concomitant tardive dyskinesia was assessed using the Abnormal Involuntary Movement Scale. The mean follow up was 103 weeks. 3. The results for the tardive dystonia: four patients recovered totally, two improved considerably and one did not recover. 4. The results for the concomitant tardive dyskinesia: five of the seven patients had also dyskinesia, one patient had a total, two a partly remission, one had a very fluctuating course, and one patient worsened. Another patient developed dyskinesia. 5. It is suggested to consider clozapine for patients with tardive dystonia who have to continue antipsychotic treatment.
authors.affiliation: Psychiatric Hospital Welterhof, Heerlen, The Netherlands.
authors.forename: P N
authors.initials: PN
authors.lastname: Van Harten
authors.forename: D J
authors.initials: DJ
authors.lastname: Kampuis
authors.forename: G E
authors.initials: GE
authors.lastname: Matroos
mesh_terms: D000328:Adult; D003024:Clozapine / Q000627:therapeutic use*; D004421:Dystonia / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines; D014230:Triazoles
chemical_list: C094949:4,5-diphenyl-1-(4-(2,6-dimethylpiperidino)-2-butynyl)-1,2,4-triazoline-5-one; C094950:4,5-diphenyl-1-(4-piperidino-2-butynyl)-1,2,4-triazoline-5-one; D010880:Piperidines; D014230:Triazoles; D003024:Clozapine